What Happens If You Stop Eye Injections for Macular Degeneration?
Stopping anti-VEGF eye injections for wet macular degeneration can allow abnormal blood vessels to become active again, increasing the risk of fluid buildup, bleeding and central vision loss. In the United States, retina specialists may consider treatment pauses, longer intervals and other options, but changes in vision such as blur, distortion or a new central blind spot should be assessed promptly.
This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.
Maintaining a consistent clinical schedule represents one of the most critical aspects of managing chronic retinal conditions. Many individuals experience significant improvements or stability in their vision after beginning treatment, which can occasionally lead to a false sense of security. When visits are paused without physician guidance, underlying processes that were merely suppressed can quickly regain momentum, creating silent risks beneath the surface of the retina.
Anti-VEGF injections for wet macular degeneration
Vascular endothelial growth factor plays a central role in stimulating the proliferation of fragile, abnormal capillaries beneath the retina. In healthy tissue, this protein supports normal circulation, but excess levels trigger damaging leakage in sensitive ocular areas. Anti-VEGF medications work by binding to these signaling proteins, effectively halting the chemical messages that cause fragile vessels to sprout and leak.
Because these therapeutic agents have a limited lifespan inside the vitreous cavity, their protective effects gradually diminish over several weeks. When an individual ceases regular administration, circulating drug concentrations drop below therapeutic thresholds. As a result, the chemical blockade lifts, allowing growth factors to resume stimulating aberrant vessel activity, which threatens the delicate neural architecture responsible for sharp central clarity.
Risk of fluid, bleeding and scar tissue
The immediate consequence of unchecked vessel proliferation is the accumulation of intraretinal or subretinal fluid. Without active medication to seal cellular junctions, weakened blood vessels begin to seep serum and blood into nearby layers of the retina. This unwanted fluid disrupts the precise alignment of photoreceptors, causing straight lines to appear wavy, distorted, or fragmented during everyday tasks.
If the exudation remains unaddressed, repeated hemorrhages and persistent edema lead to permanent structural damage. The eye attempts to heal this chronic inflammation by forming fibrous scar tissue directly under the macula. Unlike swelling, which can often resolve once therapy resumes, dense fibrous scarring permanently destroys light-detecting cells. This progression can convert a manageable visual disturbance into irreversible central blind spots that glasses or surgical procedures cannot correct.
Longer treatment intervals and monitoring
Discontinuing clinical intervention entirely is fundamentally different from a planned, medically supervised extension of treatment intervals. Many retina specialists utilize treat-and-extend regimens, gradually lengthening the time between appointments when optical coherence tomography scans demonstrate complete stability. This structured approach ensures that the interval increases only as long as the eye remains completely dry and free from new vascular activity.
Routine diagnostic scans remain mandatory even when appointments are spread further apart. High-resolution imaging detects microscopic fluid reaccumulation long before any subjective blurriness becomes noticeable to the individual. Maintaining these scheduled monitoring sessions gives the clinical team an opportunity to intervene promptly with an updated schedule, preventing irreversible damage while still reducing the overall treatment burden whenever clinically appropriate.
When vision changes need prompt review
Individuals who have delayed or paused their clinical visits must remain vigilant regarding subtle sensory shifts. A classic early warning sign involves metamorphopsia, where straight edges such as door frames, window blinds, or lines of printed text appear bent or irregular. Other indicators include sudden decreases in color vibrancy, washed-out contrast, dark patches near the center of vision, or unexpected difficulty reading familiar print.
Any acute change in clarity demands an immediate evaluation by an eye care specialist rather than waiting for an upcoming routine appointment. Prompt clinical assessment allows physicians to identify new fluid pockets or acute hemorrhages before permanent structural scarring sets in. Re-establishing anti-VEGF therapy at the first sign of reactivation offers the best probability of preserving functional vision and halting further progression.